{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-083227","form_type":"8-K","ticker":"RNA","cik":"0002093101","company_name":"Atrium Therapeutics, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.244200+00:00","generated_at":"2026-05-15T23:16:30.980344+00:00","sec_items":["1.01","5.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atrium Therapeutics completes spin-off from Avidity; begins trading under RNA on Nasdaq","bullets":["Separation of Atrium Therapeutics (SpinCo) from Avidity effective Feb 26, 2026; one SpinCo share for every ten Avidity shares distributed.","Amended License Agreement expands IP cross-licenses; Transition Services Agreement provides support services from Avidity.","Board elected: Carsten Boess, W. Michael Flanagan, Simona Skerjanec, Troy Wilson; terms expire at first/second annual meetings.","Executive officers: Kathleen Gallagher (CEO) and Brendan Winslow (CFO); employment agreements and compensatory plans adopted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-083227","json":"https://secwatch.observer/filing/0001193125-26-083227.json","markdown":"https://secwatch.observer/filing/0001193125-26-083227.md","text":"https://secwatch.observer/filing/0001193125-26-083227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/d87849d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:16:30.980344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"076b3af353f4c5e698a278aef2405054bc5133c5","claim":"Atrium Therapeutics, Inc. completed a disposition involving Avidity Biosciences, Inc. (closed 2026-02-26).","evidence_excerpt":"Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","confidence":0.9},{"claim_id":"cf87c733870e51fd9dd15fd3fe9a0c20a1de51a3","claim":"Atrium Therapeutics, Inc. entered into Transition Services Agreement with Avidity Biosciences, Inc. valued at Company and Avidity entered into a Transition Services Agreement pursuant to which Avidity will prov (effective 2026-02-26).","evidence_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","confidence":0.95},{"claim_id":"fa798de82be4b3e13fbd3141a0e1e02c83e25595","claim":"Atrium Therapeutics, Inc. entered into Amended and Restated License Agreement with Avidity Biosciences, Inc. valued at Company entered into an Amended and Restated License Agreement with Avidity, amending the original l (effective 2026-02-26).","evidence_excerpt":"On February 26, 2026, the Company entered into an Amended and Restated License Agreement (“Amended and Restated License Agreement”) with Avidity amending the original license agreement between the Company and Avidity, dated October 25, 2025 (the “Original License Agreement”), pursuant to which the Company granted to Avidity certain exclusive and non-exclusive licenses under the Company’s platform technology and other intellectual property, and Avidity granted to the Company certain exclusive and non-exclusive licenses under certain intellectual property owned or controlled by Avidity and its subsidiaries following the Separation, as further described in the section of the Information Statement (the “Information Statement”) entitled “Business—Intellectual Property—RemainCo License Agreement” filed as Exhibit 99.1 to Amendment No. 2 to the Registration Statement on Form 10 (the “Form 10”), filed by the Company with the Securities and Exchange Commission on February 17, 2026.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001193125-26-214976","ticker":"NKTR","company_name":"NEKTAR THERAPEUTICS","filed_at":"2026-05-08T23:59:59+00:00","headline":"Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO","event_type":"other_material","sec_items":["1.01","5.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214976","json":"https://secwatch.observer/filing/0001193125-26-214976.json","markdown":"https://secwatch.observer/filing/0001193125-26-214976.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm"}},{"accession":"0001213900-26-053865","ticker":"QUCY","company_name":"Quantum Cyber N.V.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Quantum Cyber increases equity distribution capacity to $100M; CFO Caragol moves to consulting role","event_type":"other_material","sec_items":["1.01","5.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053865","json":"https://secwatch.observer/filing/0001213900-26-053865.json","markdown":"https://secwatch.observer/filing/0001213900-26-053865.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1874252/000121390026053865/0001213900-26-053865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1874252/000121390026053865/ea0289661-8k_quantum.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"On May 4, 2026, Quantum Cyber N.V. (the “Company”) entered into that certain Amendment No. 1 to Equity Distribution Agreement (“Amendment No. 1”) with Maxim Group LLC (the “Sales Agent”), which amends that certain Equity Distribution Agreement, dated as of October 3, 2025, between the Company and Sales Agent (the “Original Agreement” and, together with Amendment No. 1, the “Sales Agreement”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1874252/000121390026053865/0001213900-26-053865-index.htm"}},{"accession":"0001493152-26-021753","ticker":"HWH","company_name":"HWH International Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"HWH enters $10M PIPE with warrants at $0.50/share; terminates Hapi Metaverse acquisition","event_type":"other_material","sec_items":["1.01","1.02","5.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-021753","json":"https://secwatch.observer/filing/0001493152-26-021753.json","markdown":"https://secwatch.observer/filing/0001493152-26-021753.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226021753/0001493152-26-021753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226021753/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"On May 5, 2026, HWH International Inc., a Nevada corporation (the “Company”) entered into a term sheet (the “Term Sheet”) with Smart Dynamics Technology Limited, a company incorporated in the British Virgin Islands (the “Investor”), pursuant to which the Company has agreed to sell to the Investor, for an aggregate purchase price of $10,000,000","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226021753/0001493152-26-021753-index.htm"}},{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001213900-26-063565","ticker":"AIB","company_name":"BlockchAIn Digital Infrastructure, Inc.","filed_at":"2026-06-01T20:57:13+00:00","headline":"Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063565","json":"https://secwatch.observer/filing/0001213900-26-063565.json","markdown":"https://secwatch.observer/filing/0001213900-26-063565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/ea0292328-8k_blockchain.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm"}},{"accession":"0001379785-26-000024","ticker":"BBDC","company_name":"Barings BDC, Inc.","filed_at":"2026-06-01T20:15:45+00:00","headline":"Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments","event_type":"other_material","sec_items":["1.01","1.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001379785-26-000024","json":"https://secwatch.observer/filing/0001379785-26-000024.json","markdown":"https://secwatch.observer/filing/0001379785-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/0001379785-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/bbdc-20260529.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/0001193125-26-083227-index.htm","comparable_excerpt":"Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/0001379785-26-000024-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}